SEC Filing Summary: Bioptix, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bioptix, Inc. on August 31, 2017. The report details a material definitive agreement entered into on the same date. Note: The request metadata referenced "Riot Platforms, Inc.," but the source text explicitly identifies the registrant as Bioptix, Inc.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a contractual amendment regarding a securities transaction.
Material Changes
The Company amended its Securities Purchase Agreements dated March 15, 2017. The primary change extends the period to consummate the Note Exchange from five (5) days to thirty (30) days following the receipt of Preferred Stock Authorization. All other terms of the original Purchase Agreements remain unchanged.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future performance, or discussion of general business risks. The document serves solely to disclose the amendment to the Note Exchange timeline. The full terms are incorporated by reference to Exhibit 10.1.
Investor Verification Checklist
- Verify the status of the "Preferred Stock Authorization" required to trigger the 30-day exchange period.
- Review the original Securities Purchase Agreements filed on March 16, 2017, and March 17, 2017, to understand the full context of the Note Exchange.
- Confirm whether the extension to 30 days impacts the Company's capital structure or dilution timeline.
- Check for any subsequent filings indicating if the Note Exchange was consummated within the new timeframe.